论文部分内容阅读
α-干扰素具有广谱抗病毒和免疫调节等多种生物活性,近年来国外已大量用于治疗慢性乙型肝炎,取得较好的疗效,被认为是目前治疗慢乙肝最有希望的药物。我院1990年11月～1992年2月应用重组干扰素a-2b(Intron A, Schering Corporation, USA)治疗慢乙肝,观察其疗效,耐受性和副反应,并探讨影响疗效的因素,现将观察结果报告如下。 1 资料和方法 1.l 一般资料共观察42例,男40例,女2例,年龄22～50岁(平均31.6岁),平均病程3.1年(>5年者8例)。全部病例均符合1990年上海全国肝炎会议修订的诊断标准,其中18例经肝穿活检证实诊断。治
Interferon alpha has broad-spectrum antiviral and immunomodulatory activities. In recent years, it has been extensively used in the treatment of chronic hepatitis B in foreign countries and has achieved good therapeutic effects. It is considered as the most promising drug for the treatment of chronic hepatitis B currently. Our hospital from November 1990 to February 1992 application of recombinant interferon a-2b (Intron A, Schering Corporation, USA) treatment of chronic hepatitis B, to observe its efficacy, tolerability and side effects, and to explore the factors that affect the efficacy of The observations are reported below. 1 Materials and Methods1.l general information observed a total of 42 cases, 40 males and 2 females, aged 22 to 50 years (mean 31.6 years), the average duration of 3.1 years (> 5 years in 8 cases). All cases were in line with the 1990 Shanghai Hepatitis Conference revised diagnostic criteria, of which 18 cases confirmed by liver biopsy diagnosis. rule